Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment

Future Microbiol. 2021 Mar:16:205-209. doi: 10.2217/fmb-2021-0018. Epub 2021 Feb 11.
No abstract available

Keywords: ACE2; COVID-19; SARS-CoV-2; TLR4; Toll-like receptor; angiotensin-converting enzyme 2; coronavirus; coronavirus disease 2019.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism*
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • COVID-19 / metabolism
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Enzyme Activators / pharmacology
  • Enzyme Activators / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Inflammation / virology
  • Molecular Targeted Therapy
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / isolation & purification
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use
  • Toll-Like Receptor 4 / antagonists & inhibitors*
  • Toll-Like Receptor 4 / metabolism

Substances

  • Anti-Inflammatory Agents
  • Antiviral Agents
  • Enzyme Activators
  • Sulfonamides
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2